Arena Pharma (NASDAQ: ARNA) reported Q4 EPS of $1.36, $2.12 better than the analyst estimate of ($0.76). Revenue for the quarter came in at $8.6 million versus the consensus estimate of $3.6 million.

"In 2018 we delivered the steps necessary to position Arena for long-term, sustainable growth by securing a strong cash position, generating important data for our potential first- or best-in-class compounds, and scaling the organization. We kicked off 2019 with exciting data demonstrating etrasimod's long-term efficacy and safety in an open-label extension trial, followed by the completion of the global license deal with United Therapeutics," said Amit D. Munshi, President and CEO of Arena. "We are in a great position and we look forward to continuing to build on the momentum of the last two years."

For earnings history and earnings-related data on Arena Pharma (ARNA) click here.